GlaxoSmithKline
NEWS
Hal Barron, the man who guided the reinvigoration of the pharmaceutical direction at GSK, is departing the company to be the CEO of Altos Labs.
Based on the success of a joint immuno-oncology antibody collaboration program targeting CD96, GlaxoSmithKline and 23andMe have extended their 2018 collaboration for an additional year.
GlaxoSmithKline has declined all three of Unilever PLC’s offers to acquire its Consumer Healthcare business, saying that the proposal undervalued the division’s present and further worth.
Researchers from the Medical University of Bialystok in Poland identified a gene that appears to double the risk of severe COVID-19.
The companies believe the collaboration, valued at more than $1.5 billion, for up to three small molecule therapeutics has the potential to transform oncology treatments.
Adagio cited three recent independent, in vitro studies showing that ADG20, which is currently undergoing Phase II/III clinical trials, has neutralization activity against Omicron.
BioSpace takes a look at the presentations made by Amgen, GSK and 2sevent bio at the all-virtual J.P. Morgan Conference.
A bispecific antibody discovered by Twist Bioscience and licensed to Revelar Biotherapeutics neutralizes both the Omicron and Delta variants of SARS-CoV-2 in studies with the live virus.
The indictment against the scientists point in specific to GSK’s code of conduct, which prohibits any company information from being shared externally without approval.
JOBS
IN THE PRESS